CHIDSEY JOHN

SEC source: 0001104659-26-066326 · tm2615646-1_4seq1.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,139,940

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $16.29 to $16.45, inclusive. The reporting person undertakes to provide to Norwegian Cruise Line Holdings Ltd. ("NCLH"), any security holder of NCLH, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1).

SEC source: 0001193125-26-197734 · ownership.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,305

F1 · kind: Represents common stock underlying 509 restricted share units attributable to an annual director equity award and 300 restricted share units received in lieu of an annual cash retainer for service as a director. The restricted share units shall vest on the sooner of the date of the 2027 annual shareholders' meeting of HCA Healthcare, Inc. or the first anniversary of the grant date.

SEC source: 0001104659-26-036211 · tm2610056-1_4seq1.xml · derivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,172,638

Underlying: Common Stock · 1,172,638 shares

Expires not disclosed

F3 · derivative.exercise_price: Represents a grant of performance-based restricted share units pursuant to the Award Agreement. Each performance-based restricted share unit represents a contingent right to receive between zero and two Ordinary Shares of NCLH, depending on NCLH's total shareholder return compound annual growth rate achieved during the performance period ending December 31, 2029. The number reported reflects the target number of shares underlying the performance-based restricted share units and is subject to the Reporting Person's continued employment.

F3 · derivative.exercise_date: Represents a grant of performance-based restricted share units pursuant to the Award Agreement. Each performance-based restricted share unit represents a contingent right to receive between zero and two Ordinary Shares of NCLH, depending on NCLH's total shareholder return compound annual growth rate achieved during the performance period ending December 31, 2029. The number reported reflects the target number of shares underlying the performance-based restricted share units and is subject to the Reporting Person's continued employment.

F3 · derivative.expiration_date: Represents a grant of performance-based restricted share units pursuant to the Award Agreement. Each performance-based restricted share unit represents a contingent right to receive between zero and two Ordinary Shares of NCLH, depending on NCLH's total shareholder return compound annual growth rate achieved during the performance period ending December 31, 2029. The number reported reflects the target number of shares underlying the performance-based restricted share units and is subject to the Reporting Person's continued employment.

SEC source: 0001104659-26-036211 · tm2610056-1_4seq1.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 986,940

F1 · security: Each restricted share unit represents the contingent right to receive one ordinary share of Norwegian Cruise Line Holdings Ltd. ("NCLH") upon vesting.

F2 · shares: Represents a grant of restricted share units under a Restricted Share Unit Award Agreement dated March 26, 2026 (the "Award Agreement"). The restricted share units will vest in four equal installments on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030, subject to the Reporting Person's continued employment through each applicable vesting date.

SEC source: 0001104659-26-001318 · tm261938-6_4seq1.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,686

F1 · security: Each restricted share unit represents the contingent right to receive one share of Norwegian Cruise Line Holdings Ltd.'s ("NCLH") common stock upon vesting.

F2 · shares: Represents a grant of restricted share units under NCLH's Amended and Restated 2013 Performance Incentive Plan. The restricted share units will vest in one installment on January 4, 2027.

SEC source: 0000950170-25-101052 · ownership.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 496

F1 · kind: Represents common stock underlying 496 restricted share units attributable to an annual director equity award, which shall vest on the sooner of the date of the Issuer's 2026 annual shareholders' meeting or the first anniversary of the grant date.

SEC source: 0001104659-25-010592 · tm255671-2_4seq1.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,517

F1 · security: Each restricted share unit represents the contingent right to receive one share of Norwegian Cruise Line Holdings Ltd.'s ("NCLH") common stock upon vesting.

F2 · shares: Represents a grant of restricted share units under NCLH's Amended and Restated 2013 Performance Incentive Plan. The restricted share units will vest in one installment on January 2, 2026.

SEC source: 0001127602-24-013000 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,826

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on April 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.43 to $79.62, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-013000 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,592

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-001540 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,416

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their directors fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on January 16, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $70.36 to $70.53, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-001540 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,921

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 16, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $71.45. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-026005 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,722

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their director fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferred fees and the dividend of $0.15 per share paid on October 16, 2023.

SEC source: 0001127602-23-026005 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 161,181

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 16, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $63.77. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-020892 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,959

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferral and the dividend of $0.15 per share paid on July 17,2023

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $67.70 to $67.74. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-23-020892 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,511

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $67.54. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-014824 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,302

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-013216 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,917

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on April 17, 2023.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $61.50 to $61.51, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-23-013216 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,230

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.39. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001737 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,007

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferral and the dividend of $0.15 per share paid on January 17, 2023.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $61.65 to $61.66, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-23-001737 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,325

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-024168 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,101

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferral and the dividend of $0.15 per share paid on October 17, 2022.

SEC source: 0001127602-22-024168 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,253

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-020037 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,937

F1 · shares: This number represents the purchase of (a) 654 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 349 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On July 20, 2022, the Company paid a dividend on common stock of $0.28 per share.

F2 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $50.67 to $50.73, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-22-019591 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,934

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 20, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $49.19. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-013822 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,420

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-22-012236 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,194

F2 · shares: This number represents the purchase of (a) 432 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 201 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On April 18, 2022, the Company paid a dividend on common stock of $0.28 per share.

SEC source: 0001127602-22-012236 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,561

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 18, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $71.41. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-001940 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,276

F1 · shares: This number represents the purchase of shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan"). The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director.

F2 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $62.59 to $62.60, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-22-001726 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,778

F2 · shares: Pursuant to Encompass Health Corporation's Directors Deferred Stock Investment Plan (the "Plan"), cash dividends on shares of Encompass Health common stock held under the Plan are reinvested by the Plan administrator. The Plan is a nonqualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections to defer fixed percentages of their directors fees for the following year. The deferred fees fund the purchase of Encompass Health common stock by the Plan administrator in the market for the account of each participating director and such stock is entitled to cash dividends under the Plan. On January 18, 2022, the Company paid a dividend on common stock of $0.28 per share. The transaction reported on this Form 4 is a purchase of shares of common stock of Encompass Health in the market with that dividend payment.

SEC source: 0001127602-22-001726 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,547

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 18, 2022, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $61.63. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-21-027249 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,219

F2 · shares: Pursuant to Encompass Health Corporation's Directors Deferred Stock Investment Plan (the "Plan"), cash dividends on shares of Encompass Health common stock held under the Plan are reinvested by the Plan administrator. The Plan is a nonqualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections to defer fixed percentages of their directors fees for the following year. The deferred fees fund the purchase of Encompass Health common stock by the Plan administrator in the market for the account of each participating director and such stock is entitled to cash dividends under the Plan. On October 15, 2021, the Company paid a dividend on common stock of $0.28 per share. The transaction reported on this Form 4 is a purchase of shares of common stock of Encompass Health in the market with that dividend payment.

SEC source: 0001127602-21-027249 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,005

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2021, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $67.62. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-21-022093 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,707

F2 · shares: Pursuant to Encompass Health Corporation's Directors Deferred Stock Investment Plan (the "Plan"), cash dividends on shares of Encompass Health common stock held under the Plan are reinvested by the Plan administrator. The Plan is a nonqualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections to defer fixed percentages of their directors fees for the following year. The deferred fees fund the purchase of Encompass Health common stock by the Plan administrator in the market for the account of each participating director and such stock is entitled to cash dividends under the Plan. On July 15, 2021, the Company paid a dividend on common stock of $0.28 per share. The transaction reported on this Form 4 is a purchase of shares of common stock of Encompass Health in the market with that dividend payment.

SEC source: 0001127602-21-022093 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,529

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2021, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $79.89. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-21-015981 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,278

F1 · shares: Award of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-21-013950 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,521

F2 · shares: Pursuant to Encompass Health Corporation's Directors Deferred Stock Investment Plan (the "Plan"), cash dividends on shares of Encompass Health common stock held under the Plan are reinvested by the Plan administrator. The Plan is a nonqualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections to defer fixed percentages of their directors fees for the following year. The deferred fees fund the purchase of Encompass Health common stock by the Plan administrator in the market for the account of each participating director and such stock is entitled to cash dividends under the Plan. On April 15, 2021, the Company paid a dividend on common stock of $0.28 per share. The transaction reported on this Form 4 is a purchase of shares of common stock of Encompass Health in the market with that dividend payment.

SEC source: 0001127602-21-013950 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,354

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2021, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $82.66. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-21-002083 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,118

F2 · shares: Pursuant to Encompass Health Corporation's Directors Deferred Stock Investment Plan (the "Plan"), cash dividends on shares of Encompass Health common stock held under the Plan are reinvested by the Plan administrator. The Plan is a nonqualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections to defer fixed percentages of their directors fees for the following year. The deferred fees fund the purchase of Encompass Health common stock by the Plan administrator in the market for the account of each participating director and such stock is entitled to cash dividends under the Plan. On January 15, 2021, the Company paid a dividend on common stock of $0.28 per share. The transaction reported on this Form 4 is a purchase of shares of common stock of Encompass Health in the market with that dividend payment.

SEC source: 0001127602-21-002083 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,946

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2021, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $83.42. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001104659-21-000956 · tm211588-2_4seq1.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,318

F1 · security: Each restricted share unit represents the contingent right to receive one share of Norwegian Cruise Line Holdings Ltd.'s ("NCLH") common stock upon vesting.

F2 · shares: Represents a grant of restricted share units under NCLH's Amended and Restated 2013 Performance Incentive Plan. The restricted share units will vest in one installment on January 3, 2022.

SEC source: 0001127602-20-027241 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,713

F2 · shares: This number represents the purchase of (a) 456 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 202 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2019 to defer fixed percentages of their directors fees for 2020. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On October 15, 2020, the Company paid a dividend on common stock of $0.28 per share.

SEC source: 0001127602-20-027241 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,055

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $68.11. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-021825 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,770

F2 · shares: This number represents the purchase of (a) 511 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 214 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2019 to defer fixed percentages of their directors fees for 2020. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On July 15, 2020, the Company paid a dividend on common stock of $0.28 per share.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $63.85 to $63.93, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-021825 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,045

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On July 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $65.21. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-015798 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,750

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-013952 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,446

F2 · shares: This number represents the purchase of (a) 413 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 194 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2019 to defer fixed percentages of their directors fees for 2020. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On April 15, 2020, the Company paid a dividend on common stock of $0.28 per share.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $69.43 to $69.45, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-013952 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,839

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-001987 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,572

F2 · shares: This number represents the purchase of (a) 369 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 170 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2019 to defer fixed percentages of their directors fees for 2020. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On January 15, 2020, the Company paid a dividend on common stock of $0.28 per share.

SEC source: 0001127602-20-001987 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,033

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $77.50. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001104659-20-001564 · tm201189d3_4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,787

F1 · security: Each restricted share unit represents the contingent right to receive one share of Norwegian Cruise Line Holdings Ltd.'s ("NCLH") common stock upon vesting.

F2 · shares: Represents a grant of restricted share units under NCLH's Amended and Restated 2013 Performance Incentive Plan. The restricted share units will vest in one installment on January 4, 2021.